CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country

被引:0
作者
Noor Yuhyi Sulaiman
Nur Adila Anuar
Normala Arshad
Chin Sum Cheong
Chee Chiat Liong
Shasha Khairullah
Edmund Fui Min Chin
Ping Chong Bee
I Ching Sam
Thevambiga Iyadorai
Gin Gin Gan
机构
[1] University of Malaya,Department of Medicine, Faculty of Medicine
[2] Department of Medical Microbiology,undefined
[3] Faculty of Medicine,undefined
来源
Indian Journal of Hematology and Blood Transfusion | 2024年 / 40卷
关键词
Hematopoietic stem cell transplantation; Cytomegalovirus prevalence; Cytomegalovirus infection; Southeast Asia; Malaysia;
D O I
暂无
中图分类号
学科分类号
摘要
Cytomegalovirus (CMV) infection is one of the common complications which can lead to significant morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT). As the seroprevalence of CMV infection in Malaysia is high, this study aims to determine the prevalence of CMV infection in patients post HSCT and to evaluate the associated risk factors. Patients who underwent allogeneic HSCT in adult ward from 2008 to 2020 at a tertiary teaching hospital in Kuala Lumpur, Malaysia were studied retrospectively. They were followed up for a minimum of 100 days post-HSCT to determine the incidence of CMV infection. CMV infection was defined according to CMV Drug Development Forum 2014. Risk factors such as type of transplant, serostatus of donor and patients, age, gender, race, presence of graft versus host disease (GVHD) and underlying disease were included for analysis. A total of 112 patients were included. Forty (35.7%) patients had CMV infection with median of onset recorded as 40 days (range 13–95 days). Only haplo-identical HSCT and presence of GVHD were identified as significant risk factors. Patients who had CMV infection had a lower median survival time although this was not statistically significant. The CMV infection rate was comparable with previous reports in Asia and as expected, higher than the western countries. Therefore, vigilant monitoring of CMV infection should be implemented especially in patients who had haplo-identical HSCT and acute GVHD.
引用
收藏
页码:97 / 102
页数:5
相关论文
共 48 条
  • [1] Styczynski J(2018)Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation Infect Dis Ther 7 1-16
  • [2] Lachmann R(2018)Cytomegalovirus (CMV) seroprevalence in the adult population of Germany PLoS One 13 e0200267-81
  • [3] Stadler LP(2010)Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males Clin Infect Dis 51 e76-1447
  • [4] Bate SL(2010)Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004 Clin Infect Dis 50 1439-296
  • [5] Dollard SC(2006)The prevalence of human cytomegalovirus seropositivity among blood donors at the Unit of Blood Transfusion Medicine, Hospital Universiti Sains Malaysia Southeast Asian J Trop Med Public Health 37 294-182
  • [6] Cannon MJ(1993)Prevalence of cytomegalovirus antibody in Thai-northeastern blood donors Southeast Asian J Trop Med Public Health 24 180-24
  • [7] Ahmed SA(2020)Cytomegalovirus disease in patients with hematopoietic stem cell transplantation, experience over 8 years Hematol Transfus Cell Ther 42 18-2016
  • [8] Urwijitaroon Y(2015)Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid Leukemia who survived to day 100 after transplantation: the Japan society for hematopoietic cell transplantation transplantation-related complication working group Biol Blood Marrow Transplant 21 2008-1062
  • [9] Teawpatanataworn S(2021)Human cytomegalovirus infection: a considerable issue following allogeneic hematopoietic stem cell transplantation Oncol Lett 21 318-e127
  • [10] Kitjareontarm A(2007)Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation Bone Marrow Transplant 40 1055-586